Education Library

Resources for Health Care Professionals





What Causes Thrombus Formation Among Blood-Contacting Medical Devices and What Can Be Done to Prevent Thrombosis?

October 9, 2020

Efforts to prevent thrombus formation among blood-contacting medical devices such as the Impella® heart pump include administration of anticoagulant medications such as heparin and direct thrombin inhibitors

What is the PROTECT Series?

August 25, 2020

The PROTECT Series of FDA clinical studies includes PROTECT I6, PROTECT II RCT2 (the only FDA randomized, controlled trial ever conducted for hemodynamically supported high-risk PCI), and PROTECT III. 

How is Impella CP® with SmartAssist® different from Impella CP®?

July 7, 2020

The Impella CP with SmartAssist is more technically advanced than the Impella CP to improve ease-of use and patient management. 

What is the Difference Between “Venting” and “Unloading”?

April 16, 2020

Navin Kapur, MD succinctly explains the concept of ventricular unloading.

Amin et al. 

February 24, 2020

The objective of the analysis, as stated in Amin et al., was “to describe the trends in Impella® use; variation in Impella use and its outcomes over 13 years.

Dhruva et al. 

February 21, 2020

Dhruva et al. is a retrospective, observational analysis of patients with acute myocardial infarction (AMI) complicated by cardiogenic shock undergoing percutaneous coronary intervention (PCI) between October 1, 2015 and December 31, 2017. 

Is There Randomized Controlled Trial Data Available for Impella® Heart Pump Use in Cardiogenic Shock?

February 10, 2020

Abiomed is committed to providing the best possible clinical care and evidence of beneficial effect of Impella in critically ill patients with cardiogenic shock.

How Do Bleeding Rates with Impella® Compare to Bleeding Rates Associated With Other Forms of Mechanical Circulatory Support?

November 15, 2019

Data from the PROTECT II randomized controlled trial show that patients treated with Impella had numerically lower rates of vascular complications compared with patients treated with intra-aortic balloon pump (1.4% for Impella versus 1.9% for IABP).1

Right Heart Failure and the Impella RP® Heart Pump

August 2, 2019

This FAQ discusses the causes, incidence, and diagnosis of right heart failure and how the Impella RP(R) heart pump can support the right side of the heart.

What is the STEMI DTU™ Pivotal Trial?

August 2, 2019

The STEMI DTU pivotal trial is a prospective, multicenter, two-arm randomized controlled trial that plans to enroll 668 patients undergoing treatment for a STEMI heart attack. 

What is the purpose of the STEMI DTU™ RCT?

July 9, 2019

The pivotal trial will build on the promising results of the successful STEMI DTU safety and feasibility trial, or STEMI DTU pilot trial, which met its goal by demonstrating it is safe and feasible to conduct

What Is the Real-World Evidence That Supports the Benefit of Placing the Impella® Heart Pump Pre-PCI?

June 19, 2019

A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardiogenic Shock Initiative support the recommendation that placing Impella 2.5 or Impella CP pre-PCI improves outcomes.

What is NCSI Study?

November 5, 2018

The NCSI Study is based on adopting the best practices algorithm focused on identifying shock early and unloading using Impella devices before PCI, reducing use of inotropes, and the use of invasive hemodynamic monitoring to aid in escalation and weaning.

What is the STEMI DTU Pilot Trial?

November 5, 2018

The STEMI DTU pilot trial demonstrated for the first time that LV unloading using the Impella CP® heart pump with a 30-minute delay before reperfusion is safe and feasible

What is A-CURE?

November 5, 2018

The clinical, preclinical, and basic research of A-CURE focuses primarily on the use of the Impella® heart pump, a transvalvular microaxial flow pump, as the means to unload the heart.